33 results about "Stromal cell" patented technology

The current invention relates to a composition comprising extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs). The EVs are part of a population of particles in the composition having a particle size of between 0.05 and 0.22 micron. The concentration of these particles is at least 1×1011 particles per ml of composition. At least 90% of the particles with particle size of between 0.05 and 0.22 micron are EVs. The EVs are defined by having a concentration of intra-vesicular Annexin V of at least 40 ng / ml and a concentration of extra-vesicular Annexin V of less than 1 ng / ml. Uses of the composition also are disclosed.

This invention belongs to the field of biomedical technology, specifically relating to a rapid purification method for umbilical cord MSC exosomes and their application in the preparation of drugs for treating COPD. This invention discloses a method for rapidly purifying umbilical cord mesenchymal stromal cell (MSC) exosomes and a pharmaceutical composition comprising umbilical cord MSC exosomes and yamosaponin. In this pharmaceutical composition, the umbilical cord MSC exosomes and yamosaponin synergistically enhance the dynamic compliance of COPD rats, reduce airway resistance, decrease pulmonary inflammation, and repair pulmonary dysfunction. This invention provides a new technical solution for the preparation of drugs for treating or improving COPD.

This invention belongs to the field of biomedical technology, specifically relating to the application of mesenchymal stem cells in the preparation of anti-aging drugs. The mesenchymal stem cells are human adipose-derived mesenchymal stem cells (hAMSCs) or mouse bone marrow mesenchymal stem cells (BM-MSCs). This invention utilizes mesenchymal stem cells to regulate senescent stromal cells and the spleen's ECM, improving the thinning stromal state in the tissue microenvironment through multiple targets. Specifically, it improves the aging-related secretory phenotype of stromal cells, enhances mitochondrial activity, strengthens their proliferation capacity, and delays the reduction of collagen secretion. This, in turn, delays the disordered distribution and functional decline of immune cells caused by aging and enhances tissue regeneration capacity, indirectly affecting various other cells in the tissue microenvironment, thus exhibiting an antagonistic effect against systemic organ aging.

The present application relates to the technical field of biological medicine, and more particularly to a culture solution, a kit and an application for in-vitro maturation of aged oocytes. Through in-vitro experiments, the present application adds exogenous stromal cell-derived factor 1, establishes a culture system for in-vitro maturation of aged oocytes, and reveals the molecular mechanism of stromal cell-derived factor 1 playing a role through autophagy, thereby providing a new solution for improving the fertility of aged women and improving the success rate of assisted reproductive technology, and having important clinical application value.

The present disclosure relates to allogeneic populations of mesenchymal stem / stromal cells and related compositions, which populations and compositions comprise cells pooled from multiple donors, and their use in therapy and / or prevention of inflammatory, autoimmune, transplant related and CNS disorders, in particular CNS such as Amyotrophic Lateral Sclerosis. The present disclosure also relates to methods for obtaining said compositions.

The embodiment of the application relates to the technical field of medical coating materials, and particularly relates to a method for forming an active coating on the surface of a degradable occlusion device and the degradable occlusion device, the method comprising the following steps: preparing perfluorohexane liposomes loaded with stromal cell-derived factor-1 alpha (SDF-1 alpha); preparing polylactic acid-glycolic acid copolymer@rapamycin@nitric oxide donor nanoparticles; preparing a methacrylated gelatin-tannic acid hydrogel carrier; mixing the liposomes and the nanoparticles into the hydrogel carrier; soaking the degradable occlusion device in the mixture obtained in the previous step, and performing light crosslinking treatment on the mixture, so that an active coating is formed on the surface of the degradable occlusion device. Therefore, comprehensive consideration of "endothelialization repair in the early implantation period - myocardial tissue remodeling after implantation" is realized, controllable time-sequencing repair of the degradable occlusion device on the heart defect site is ensured, and the endogenous functional repair effect of the heart of a patient is improved.

Provided herein is an immortalized MSC that heterologously expresses p53-upregulated-regulator-of-p53-levels (PURPL) lncRNA. Also provided is a method for making an immortalized MSC comprising heterologously expressing PURPL lncRNA in an MSC. Also provided are methods for treating a disease in a subject in need thereof comprising administering to the subject the immortalized MSC described herein or made by the methods described herein.

The present disclosure relates to adipose-derived regenerative cell (ADRC) preparations and methods of culturing ADRCs to obtain ASCs. In particular the present disclosure relates to adipose-derived stromal cells derived from these cultures and their use in treatment.

This invention relates to peptides with activity that promotes hair growth or prevents or inhibits hair loss. The peptides of this invention promote the proliferation of human follicular dermal papilla cells (HFDPC), activate cell proliferation-related signaling proteins and β-catenin in HFDPC, enhance the expression levels of downstream genes of β-catenin, downregulate the expression level of the hair loss protein DKK-1, increase the expression of keratin in hair follicle outer root sheath cells (HORSC), and upregulate the expression of transcription factors involved in cell activation in germinal stromal cells (GMC).

This invention relates to the pharmaceutical field, specifically to a drug for the prevention or treatment of endometrial fibrosis, comprising poloxamer and spermidine; poloxamer is added to the spermidine solution and swelled at 3-5°C until completely dissolved to form a liquid precursor; the liquid precursor undergoes a phase transition at 35-40°C to form a gel; the liquid precursor is injected into the uterine cavity to reduce the expression of αSMA in the endometrial tissue, inhibit the transformation of stromal cells into myofibroblasts, and promote angiogenesis.

The present disclosure relates to an ultrasound guided intraarticular administration of a combination of a composition comprising pooled mesenchymal stromal cells, and mid molecular weight hyaluronic acid for treatment of osteoarthritis. The disclosure also provides methods for increasing levels of anti-inflammatory marker and decreasing levels of disease progression marker in a human subject suffering from osteoarthritis through the use of the said combination. The present disclosure accordingly also relates to a kit comprising the said composition and the hyaluronic acid as such for the said use and treatment.

This invention relates to the field of cell image analysis and biological cell screening technology, and discloses a method for screening liver stem cells. The method includes: acquiring original images; performing effective image screening; performing background correction, noise reduction and enhancement, and contrast compensation; performing single-cell instance segmentation; performing single-cell feature extraction and trajectory association; determining target cells using a neural network model; and outputting the liver stem cell determination result. Compared to existing screening methods that rely on manual observation or single-frame static image discrimination, especially in the case of primary hepatocyte suspensions containing mature hepatocytes, bile duct epithelial cells, stromal cells, and cell debris, this method addresses the technical problem of unstable and automated identification of liver stem cells. This application improves the accuracy and automation of liver stem cell screening by constructing a continuous processing flow of image quality gating, instance segmentation, and dual-branch feature fusion judgment.

This invention relates to the expansion of non-haematopoietic tissue-resident γδ T cells in vitro by culturing lymphocytes obtained from non-haematopoietic tissue of humans or non-human animals in the presence of interleukin-2 (IL-2) and / or interleukin-15 (IL-15) and the absence of TCR activation or co-stimulation signals, without any direct contact with stromal or epithelial cells. Methods of non-haematopoietic tissue-resident γδ T cell expansion are provided, as well as populations of non-haematopoietic tissue-resident γδ T cells and uses thereof.

This specification describes a method for treating kidney disease, comprising administering a cell-derived product to the patient's perirenal adipose tissue (PRAT) in patients requiring treatment for kidney disease. Optionally, the cell-derived product is a plurality of mesenchymal stromal cells. Other diseases, including liver disease, cardiovascular disease, inflammatory disease, fibrous disease, autoimmune disease, and visceral disease, can be treated using this method.

This invention belongs to the field of biomedical technology, specifically relating to an umbilical cord MSC exosome nanocarrier delivery system and its application in the preparation of drugs for treating allergic rhinitis. This invention prepares the umbilical cord MSC exosome nanocarrier delivery system by adding a specific concentration of diosgenin to the culture medium of umbilical cord mesenchymal stromal cells (MSCs), collecting the cell culture supernatant, and separating and extracting it. Animal experiments show that the delivery system prepared in this invention significantly improves the symptoms of nose scratching and sneezing in mice with allergic rhinitis. Its mechanism of action lies in effectively regulating the Th1 / Th2 immune balance: significantly inhibiting the overexpression of the pro-inflammatory factor IL-4, while simultaneously restoring the anti-inflammatory factor IL-10, thus avoiding immune dysregulation. This invention provides a safe and effective new treatment for allergic rhinitis and has good clinical application prospects.

Pharmaceutical and / or cosmetic formulations containing artificial peptides and their medical uses are described, the artificial peptides being characterized by proline sequences that are ubiquitous in key stromal cell proteins involved in wound healing, bone and cartilage formation, and the maintenance of connective tissue in all vertebrates. This invention relates to a pharmaceutical formulation in gel form, comprising a. a substance comprising Pro-X-X-Pro-Y-Y-Y-Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-Y-Y-Y-Y-Pro-Y-Y-Y-Pro-Y-Y-Y-Y-Pro-X-X-Pro-X-Pro-Y-Y-Y-Y-Pro-X-X-Pro-Y-Y-Y-Pro-Y-Y-Pro-X-X-Pro-Y-Y-Pro-Y-Pro-X-X-Pro-Y-Pro-Y-Pro-X-X-Pro-Y-Pro-Y-Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-Y-X ... Artificial peptides comprising the amino acid sequence of NO:1) and / or artificial peptides comprising or composed of the amino acid sequence Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-Y-Y-Pro-X-X-Pro-Y-Y-Pro-X-Pro-X-Pro-Pro (SEQ ID NO:2), wherein i) Pro is proline; ii) X is an amino acid selected from Ala, Ile, Leu, Met, Phe, Trp and Val; iii) Y is an amino acid selected from Asn, Cys, Gln, Ser, Thr and Tyr; b. cross-linked hyaluronic acid fibers (HA-XL) and c. linear hyaluronic acid fibers (HA).

The embodiment of the application discloses a composite material containing umbilical cord mesenchymal stromal cell exosome combined with ECM and a preparation method and application thereof, and belongs to the technical field of biological medicine. The composite material comprises the following raw materials in parts by weight: 15-25 parts of umbilical cord mesenchymal stromal cell exosome, 50-75 parts of ECM, and 10-20 parts of stabilizer. The composite material provided by the application has excellent wound repair activity, can significantly promote the transformation of a chronic wound from an inflammation period to a proliferation period, accelerate the processes of angiogenesis, granulation tissue formation and epithelialization, and can be applied to the repair of chronic skin wounds such as diabetic foot ulcers, venous ulcers and pressure injuries.

The application discloses application of leptin in preparation of a medicine for promoting hair growth, and belongs to the technical field of biological medicines. The leptin provided in the application is expressed in hair matrix cells of a growing hair follicle, activates a JAK-STAT signal path, and induces continuous proliferation of hair matrix cells, so as to promote the hair follicle to enter the growing period in advance, prolong the time length of the growing period of the hair follicle, promote differentiation of the hair matrix cells into keratinocytes, maintain continuous growth of the hair shaft, and further prolong the length of the hair shaft.

This invention discloses the application of bavachin in the preparation of drugs for alleviating and / or preventing senescence of uterine decidual stromal cells, belonging to the field of biomedical technology. Through drug library screening and experimental verification, this invention found that bavachin can significantly alleviate the senescent phenotype of human uterine decidual stromal cells, reduce the expression of senescence-related markers, and alleviate decidual stromal cell senescence by regulating intracellular copper ion metabolism and transport to maintain intracellular and extracellular copper ion homeostasis. This invention provides a novel drug target and intervention strategy for clinically improving endometrial decidual function and treating related reproductive health problems. This invention also provides the application of bavachin in the preparation of drugs for alleviating senescence of uterine decidual stromal cells.

Method for producing a three-dimensional human multiple myeloma model. The present invention relates to a method for producing a three-dimensional (3D) model of multiple myeloma (MM), in the form of spheroids, by co-culturing mesenchymal stem / stromal cells, endothelial progenitor cells, and primary plasma cells from MM patient(s). The present invention also relates to the spheroids obtained by said method and their uses. Figure for abstract: none

This invention relates to the field of biotechnology, specifically, to a method for culturing endometrial organoids. By optimizing the endometrial organoid differentiation and culture system, compared to existing methods, the optimized system is simple to operate, does not require co-culturing with stromal cells to prepare organoids with more complete physiological functions, and can be cultured continuously for at least one year. The resulting organoids exhibit complete secretory function and a more pronounced ciliated cell phenotype.

The present application relates to the technical field of cell induced differentiation culture and cell culture medium preparation, and provides a cell culture medium and a use thereof in inducing the directional differentiation of olfactory mucosa mesenchymal stromal cells into melanocytes. The culture medium has a clear composition, and the components used are all conveniently and readily available mature commercial components. The culture medium can be used to induce olfactory mucosa mesenchymal stromal cells into melanocytes expressing tyrosinase and containing melanin particles, and has the advantages of a simple induction method and autoinduction to avoid ethical problems. In addition, the olfactory mucosa mesenchymal stromal cells are isolated from the nasal mucosa tissue, the nasal mucosa tissue is conveniently available, the nasal region has an abundant blood supply, and the wound is small and heals rapidly without causing continuous damage to the human body. The prepared melanocytes can be used as seed cells for treating vitiligo diseases and have wide prospects.

The present invention relates to antigen binding proteins that specifically bind to SCGF and comprises their use in the treatment of cancer inflammation and trauma. Also the present invention relates to nucleic acids encoding the antigen binding proteins, vectors comprising said nucleic acids and host cells comprising said expression vectors. Further, the invention relates to pharmaceutical compositions comprising said antigen binding protein and kits comprising said pharmaceutical compositions.

The application relates to the technical field of mesenchymal stromal cells, in particular to a method for detecting the chondrogenic differentiation capacity of mesenchymal stromal cells, a method for screening mesenchymal stromal cells and application. The method comprises the following steps: culturing mesenchymal stromal cells of any generation from the third to the seventh generation in three dimensions, detecting the contents of COMP and TSP2 in the supernatant of the cells after the culture, and detecting the chondrogenic differentiation capacity of the mesenchymal stromal cells or screening the mesenchymal stromal cells according to the contents of COMP and TSP2. The application solves the technical problems that the mesenchymal stromal cells are highly heterogeneous, the chondrogenic differentiation detection method is unstable, and there is a lack of objective and quantifiable judgment standard in the prior art, and provides a standardized, scaled and high-accuracy cell quality control method and high-quality cell screening scheme for the field of cartilage regeneration.

The application discloses application of Biochanin A in preparation of a medicine for inhibiting or improving uterine decidua stromal cell senescence, and belongs to the field of biomedical technology. Through drug chemical library screening and experimental verification, it is found that Biochanin A can significantly alleviate the senescence phenotype of human uterine decidua stromal cells, reduce the expression of senescence-related markers, and alleviate decidua stromal cell senescence through regulation of mitochondrial energy metabolism. The application provides a brand-new drug target and intervention strategy for improving endometrial decidua function and treating related reproductive health problems in clinic, and provides application of Biochanin A in preparation of a medicine for alleviating uterine decidua stromal cell senescence.

The present disclosure relates to compositions, apparatus and methods for generating one or more scaffolds, including: mixing a hydrogel material and / or an extracellular matrix (ECM) protein in an aqueous solvent to generate an aqueous process solution; and cryoelectrospinning the aqueous process solution onto a plurality of conductive probes extending from a conductive surface of a collector plate disposed within a process chamber under conditions sufficient to generate one or more scaffolds configured to mimic a preselected soft tissue decellularized extracellular matrix. Scaffold compositions are also provided having preselected or tuned characteristics. The scaffolds provide a promising stromal cell delivery vehicle for the remediation of fibrosis.